Botulinum toxin type A + Botulinum toxin type A + Botulinum toxin type A + Botulinum toxin type A

Phase 3Active

0 views this week 0 watching⚡ Active

Interest: 41/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Episodic Migraine

Conditions

Episodic Migraine

Trial Timeline

Sep 29, 2023 → Dec 4, 2026

NCT ID

NCT06047457

About Botulinum toxin type A + Botulinum toxin type A + Botulinum toxin type A + Botulinum toxin type A

Botulinum toxin type A + Botulinum toxin type A + Botulinum toxin type A + Botulinum toxin type A is a phase 3 stage product being developed by Ipsen for Episodic Migraine. The current trial status is active. This product is registered under clinical trial identifier NCT06047457. Target conditions include Episodic Migraine.

What happened to similar drugs?

3 of 15 similar drugs in Episodic Migraine were approved

Approved (3) Terminated (1) Active (11)

✅Atogepant + UbrogepantAbbVieApproved

✅AMG334 + Oral ProphylacticNovartisApproved

✅MethylprednisoloneBrain BiotechApproved

🔄DFN-11Dr. Reddy's LaboratoriesPhase 3

🔄GalcanezumabEli LillyPhase 3

🔄Galcanezumab + PlaceboEli LillyPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06047444	Phase 3	Active	Oct 12, 2023	Dec 4, 2026	Chronic Migraine
NCT06047457	Phase 3	Active	Sep 29, 2023	Dec 4, 2026	Episodic Migraine

Competing Products

19 competing products in Episodic Migraine

See all competitors

Product	Company	Stage	Hype Score
DFN-11	Dr. Reddy's Laboratories	Phase 3	37
Galcanezumab	Eli Lilly	Phase 3	40
Galcanezumab + Placebo	Eli Lilly	Phase 3	44
Galcanezumab + Placebo	Eli Lilly	Phase 3	40
Galcanezumab + Placebo	Eli Lilly	Phase 3	40
BOTOX + Placebo	AbbVie	Phase 3	32
Atogepant 60 mg	AbbVie	Phase 3	40
Atogepant + Ubrogepant	AbbVie	Approved	43
Atogepant + Placebo-Matching Atogepant	AbbVie	Phase 3	47
SOM230 + Placebo	Novartis	Phase 2	27
AMG334 + Oral Prophylactic	Novartis	Approved	43
AMG334 (70 mg) Pre-Filled Syringe (PFS) + Placebo Pre-Filled Syringe (PFS)	Novartis	Phase 3	40
Erenumab	Novartis	Phase 3	40
Placebo + AMG 301	Amgen	Phase 2	35
Placebo + MS Contin (morphine sulfate, controlled release) + EMBEDA (morphine sulfate / naltrexone hydrochloride)	Pfizer	Phase 1	29
Eptinezumab + Placebo	Lundbeck	Phase 3	44
Eptinezumab + Placebo	Lundbeck	Phase 3	37
IPN10200 + IPN10200 dose A + IPN10200 dose B	Ipsen	Phase 2	39
Methylprednisolone	Brain Biotech	Approved	33